Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Curr Drug Metab. 2010 Oct;11(8):659–666. doi: 10.2174/138920010794233495

Figure 4.

Figure 4

Studies using wild-type and Tg-CYP2D6 mouse model demonstrate that CYP2D6 status has significant impact on harmaline pharmacokinetics (A) and harmaline-induced hypothermia (B) [113].